GLP-1 (Glucagon-like Peptide-1) receptor agonists are rapidly reshaping the health and nutrition landscape. With an estimated 6% of Americans, 20 million people, now using these metabolic therapies, emerging data on user behavior is now available and the broader impact on the food and ingredient industries is becoming clearer.

While traditional weight management products are seeing a decline, there is rising demand in categories that support common physiological effects of GLP-1 medication use. Users of GLP-1 medications are increasingly prioritizing products that support metabolic health and muscle preservation. Digestive supplements and blood glucose management products are seeing considerable growth. These trends are reinforced by clinical trials demonstrating that GLP-1 therapies often lead to reduced appetite, altered nutrient intake, and significant lean mass loss alongside fat loss—highlighting the need for supportive nutrition strategies to optimize health outcomes.

Food and ingredient companies are innovating to meet the evolving needs of this growing consumer segment. Product development is shifting toward smaller portion sizes with enhanced nutrient density, targeted formulations to mitigate gastrointestinal side effects, and products designed to support glycemic control and preserve muscle mass.

While the widespread adoption of GLP-1 receptor agonists is driving a measurable shift in consumer health priorities, the market, backed by clinical research, is adapting with targeted and innovative products that support individuals in achieving sustainable weight management and improved metabolic health.